AtriCure, Inc. (ATRC)
NASDAQ: ATRC · Real-Time Price · USD
31.83
-2.54 (-7.39%)
Mar 28, 2025, 4:00 PM EDT - Market closed
AtriCure Revenue
In the year 2024, AtriCure had annual revenue of $465.31M with 16.55% growth. AtriCure had revenue of $124.28M in the quarter ending December 31, 2024, with 16.64% growth.
Revenue (ttm)
$465.31M
Revenue Growth
+16.55%
P/S Ratio
3.21
Revenue / Employee
$357,928
Employees
1,300
Market Cap
1.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 465.31M | 66.06M | 16.55% |
| Dec 31, 2023 | 399.25M | 68.87M | 20.84% |
| Dec 31, 2022 | 330.38M | 56.05M | 20.43% |
| Dec 31, 2021 | 274.33M | 67.80M | 32.83% |
| Dec 31, 2020 | 206.53M | -24.28M | -10.52% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ATRC News
- 16 days ago - AtriCure to Host Analyst & Investor Day on March 26, 2025 - Business Wire
- 6 weeks ago - AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results - Business Wire
- 2 months ago - AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 2 months ago - AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day - Business Wire
- 3 months ago - AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 months ago - AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 5 months ago - AtriCure to Participate in the Stifel 2024 Healthcare Conference - Business Wire